5d 1m 3m 1y 5y 10y
There are no Transcripts on PJP.
PJP vs. ETF Alternatives
The PowerShares Dynamic Pharmaceuticals Portfolio (Fund) is based on the Dynamic Pharmaceuticals Intellidex Index (Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.
See more details on sponsor's website
See more details on sponsor's website
Friday, Feb 1411:35 AM
Friday, Feb 1411:35 AM| 4 Comments
- For the first time since 2006, the forward P/E ratio of health care stocks (XLV) is above that on consumer staples (XLP), according to BAML (via Matthew Boes).
- The crossover comes after more than a year of strong outperformance for healthcare names, with XLV up 47% vs. XLP up 21.3% since the start of 2013.
- Related ETFs: IYH, IBB, XLV, XLP, XBI, VHT, BIB, PJP, BBH, VDC, FBT, XPH, CURE, PBE, IHE, FXH, RXL, IRY, IXJ, IHI, PPH, IHF, PSCH, XHS, FHLC, FXG, BIS, RYH, RHS, PSL, PTH, FSTA, XHE, AXHE, PSCC, DRGS, RXD
Thursday, Sep 122013, 10:07 AM
Thursday, Sep 122013, 10:07 AM| Comment!
- U.S. bio-pharmaceutical companies are developing 271 vaccines to prevent and even treat numerous conditions, a report from the Pharmaceutical Research & Manufacturers of America says.
- The conditions targeted include infectious diseases and various forms of cancer and neurological disorders.
- In the U.S., 10 infectious diseases have been at least 90% eradicated because of vaccines.
- ETFs: XLV, XHE, VHT, FXH, IHF, IHI, IYH, PTH, RYH, PSCH, RXL, RXD, XHS, XPH, IHE, PJP, PPH, DRGS
Monday, May 62013, 1:36 PMMerck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. |Monday, May 62013, 1:36 PM| Comment!
Monday, Apr 302012, 5:20 AMPure pharmaceuticals players, like AstraZeneca (AZN), Bristol-Myers (BMY) and Eli Lilly (LLY), are likely to face higher earnings pressure over the next three years than more-diversified firms like J&J (JNJ) or Bayer (BAYRY.PK), says Fitch. Cash-rich pure-players with a relatively weak R&D pipeline, like AZN, may be tempted to go on buying sprees. |Monday, Apr 302012, 5:20 AM| Comment!
Tuesday, Apr 172012, 1:29 PMExpress Scripts (ESRX +2.5%) says prescription drug spending fell to 2.7% growth in 2011 - the slowest pace in 18 years - due to the introduction of generic medicines that tempered price increases. The company notes that the average co-payment for consumers fell to $12.02 a prescription from $12.10 a year before. |Tuesday, Apr 172012, 1:29 PM| Comment!
Tuesday, Apr 32012, 10:04 AMPush comes to shove as pricey life-saving cancer drugs run up against government austerity programs and private payers unwilling to share costs for drugs that run as high as $100K a year. While Big Pharma argues that advanced technology will save money on the development side, companies such as PFE, BMY, RHHBY, and BAYRY.PK run the risk of seeing reduced profits with government-mandated price cuts for their most expensive drugs. |Tuesday, Apr 32012, 10:04 AM| 4 Comments
Wednesday, Mar 142012, 2:33 PM
Wednesday, Jan 182012, 12:01 PMResearch from Frost & Sullivan breathes some life into the potential for generic drug makers with its new projections that the global market for generics could tip the scales at $231B in 2017 - repping an annual growth rate of close to 10%. The biggest drivers for the stellar growth should be blockbuster drugs that fall off their patents and the "huge potential" for copycat drug sales in emerging markets such as China, India, and Brazil. |Wednesday, Jan 182012, 12:01 PM| Comment!
Friday, Jan 132012, 1:35 PMAffymax (AFFY -0.3%) CEO John Orwin says the days of biotech companies seeing their share price bid up on potential is over, as investors wait it out to see if firms hash out issues with reimbursements, regulatory hurdles, and safety concerns. "There was a time when products got full value prior to launch. I think we have now swung back in the other direction." |Friday, Jan 132012, 1:35 PM| Comment!
Tuesday, Dec 272011, 2:54 PMReuters' John Wasik identifies health care as a sector that will grow in 2012 on the strength of a long-term demographic trend that is pushing up demand for medical services, devices, and pharmaceuticals. He argues that while big pharma ETFs could see a gain, a focus on generic pharmaceutical names looks to be an even better bet as governments and companies look to cut costs. Big pharma ETFs: XPH, IHE, PJP, PPH, DRGS. Generic pharma firms: IPXL, MYL, PRX, TEVA, WPI, PRGO. |Tuesday, Dec 272011, 2:54 PM| Comment!
Tuesday, Dec 272011, 5:25 AMIt could be a very tough year for pharmaceutical firms, which face a slew of patent expiries and new costs from healthcare reforms. Market research firm CreditSights pegs Bristol-Myers (BMY) and Eli Lilly (LLY) as likely to be next year's hardest-hit pharmas, while Abbott (ABT) and J&J (JNJ) will remain relatively sheltered. |Tuesday, Dec 272011, 5:25 AM| Comment!
Wednesday, Dec 142011, 7:50 AMFitch is establishing a negative 2012 outlook for pharmaceutical companies, arguing soft demand, patent expirations, and government spending cuts will take a toll on the industry; the patent expirations (I, II, III) are seen affecting LLY, BMY, and PFE the most. Fitch also sees pharmas responding to these challenges by stepping up their M&A activity. |Wednesday, Dec 142011, 7:50 AM| Comment!
Tuesday, Dec 62011, 12:48 PMSanford Bernstein analyst Tim Anderson's take on Eli Lilly (LLY +3.3%) offers a surprisingly candid view on the roulette-like risks involved in betting on drug company stocks with his estimate that LLY could clear $9B in sales of solanezumab by 2020 or misfire completely with its investment. Anderson on the sector: "Eli Lilly and several of its competitors are willing to spend hundreds of millions of dollars on what is essentially a massive lottery ticket." |Tuesday, Dec 62011, 12:48 PM| Comment!
Friday, Sep 232011, 1:53 PMShares of MannKind (MNKD +11%) go on a tear after the firm announces a plan to offer $370M in senior secured discount notes to be used in part to develop Phase 3 clinical trials of its AFREZZA product. The move follows up last month's FDA clearance on late-stage trials for the inhaled insulin therapy. |Friday, Sep 232011, 1:53 PM| 1 Comment
Wednesday, Aug 102011, 12:08 PMAnalysts continue to beat the drum for Pfizer PFE witnessed by JPMorgan reiterating an Overweight rating on shares with a $25 price target, following Goldman Sachs adding the firm to its Conviction Buy List yesterday. Shares are down 1.4%, standing as the leader for Dow components on the day. |Wednesday, Aug 102011, 12:08 PM| 5 Comments
Monday, Aug 12011, 3:56 PMCiti lowers its price target on Auxilium Pharmaceuticals (AUXL -6.6%) to $22 from $27 saying expectations on revenue from the firm's Xiaflex are too high. Earlier the firm issued its own downward guidance on FY11 revenue derived from the drug to a range of $45M-$50M from $50M-$60M. |Monday, Aug 12011, 3:56 PM| Comment!